Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Fudan University is the lead sponsor of 472 current clinical trials in our China register. 308 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Bevacizumab, Tislelizumab and Capecitabine. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting30865%
Not yet open10723%
Active, closed5111%
By invitation61%

Trials by phase

Phase 220944%
Observational8919%
Not applicable7115%
Phase 36213%
Phase 1/2194%
Phase 4112%
Phase 2/351%
Phase 131%
Phase EARLY_PHASE131%

Clinical trials sponsored by Fudan University

472 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) NCT07019363 · Breast Cancer, Adjuvant Therapy	Phase 3	Recruiting	2025-06	China
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection NCT06166147 · Pancreatic Cancer	Observational	Recruiting	2023-12	China
Reverse HER2-negative Immune Resistant Breast Cancer NCT06731140 · ClinicalTrials.gov ↗ · HER2 Negative Breast Cancer	Phase 2	Recruiting	2025-02	China
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer NCT06250972 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma	Phase 3	Recruiting	2024-05	China
Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT NCT07557654 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2026-05	China
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab NCT07047586 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC) Drugs: Lenvatinib, Tislelizumab	Phase 2	Recruiting	2025-07	China
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC NCT07398937 · ClinicalTrials.gov ↗ · Resectable Stage II-IIIa Squamous NSCLC Drugs: Nivolumab, Serplulimab	Phase 2	Recruiting	2026-02	China
Neoadjuvant SNF Precision Therapy Phase III NCT06913777 · ClinicalTrials.gov ↗ · Neoadjuvant Therapy Drug: Famitinib	Phase 3	Recruiting	2025-04	China
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer NCT05954078 · ClinicalTrials.gov ↗ · High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation	Phase 3	Recruiting	2023-08	China
Multicentric Database for KRAS Mutant Pancreatic Cancer NCT07557849 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Observational	Recruiting	2026-05	China
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer NCT05628038 · ClinicalTrials.gov ↗ · Recurrent Rectal Cancer Drugs: 5FU, Bevacizumab, Capecitabine	Phase 2	Recruiting	2022-11	China
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases NCT07623577 · ClinicalTrials.gov ↗ · TNBC, Brain Metastasis Drugs: Bevacizumab, Sacituzumab tirumotecan	Phase 2	Recruiting	2026-01	China
Station 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLC NCT07801430 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Not applicable	Recruiting	2025-12	China
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma NCT07328009 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC) Drugs: Camrelizumab, HAIC, Iparomlimab and Tuvonralimab	Phase 2	Recruiting	2026-01	China
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer NCT04281641 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Not applicable	Recruiting	2020-04	China
Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer NCT05086614 · ClinicalTrials.gov ↗ · Stage II Colorectal Cancer, Stage III Colorectal Cancer Drug: Thymalfasin	Phase 3	Recruiting	2021-04	China
Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment NCT07711171 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus, Cognitive Impairment Drugs: Acarbose, Sitagliptin	Phase 4	Recruiting	2024-08	China
Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer NCT06911528 · ClinicalTrials.gov ↗ · Breast Cancer, Sentinel Lymph Node, Frozen Section	Not applicable	Recruiting	2024-01	China
The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy NCT07757165 · ClinicalTrials.gov ↗ · Advanced Metastatic Gastric Cancer	Phase 2	Recruiting	2025-11	China
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy NCT05772208 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma Drugs: Camrelizumab, Nimotuzumab	Phase 3	Recruiting	2022-01	China
Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model NCT06202404 · ClinicalTrials.gov ↗ · Metastasis, Predictive Cancer Model	Observational	Recruiting	2024-01	China
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer NCT06591650 · ClinicalTrials.gov ↗ · Gallbladder Cancer Unresectable Drugs: Cisplatin, Durvalumab, Gemcitabine Hydrochloride	Phase 2	Recruiting	2024-10	China
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma NCT04512534 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma	Phase 2	Recruiting	2020-11	China
Zhongshan Ketogenic Diet Study 1 NCT07117903 · ClinicalTrials.gov ↗ · Platelet Function and Thrombus Formation	Not applicable	Recruiting	2025-08	China
Pinoxin for the Prevention of Radiation-Induced Skin Injury NCT07545720 · ClinicalTrials.gov ↗ · Cancer Patients Undergoning Radiotherapy	Phase 2	Recruiting	2024-09	China
Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer NCT07777536 · ClinicalTrials.gov ↗ · Thyroid Cancer	Phase 2	Recruiting	2026-08	China
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors NCT06684327 · ClinicalTrials.gov ↗ · Paget Disease, Extramammary, Rhabdomyosarcoma, Testicular Cancer Drug: Albumin paclitaxel	Phase 2	Recruiting	2024-11	China
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer NCT06196788 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drugs: Gemcitabine, Nab-paclitaxel	Phase 2	Recruiting	2024-03	China
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer NCT05883852 · ClinicalTrials.gov ↗ · HER2 Positive Early Breast Cancer	Phase 3	Recruiting	2023-06	China
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy NCT06249321 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Radiotherapy Drugs: IMRT, MFOLFIRINOX	Phase 2	Recruiting	2024-04	China
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas NCT06914674 · ClinicalTrials.gov ↗ · Pancreatic Neoplasms	Phase 2	Recruiting	2025-03	China
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) NCT05717803 · ClinicalTrials.gov ↗ · Segmentectomy, Lung Adenocarcinoma	Phase 3	Recruiting	2023-02	China
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) NCT06749015 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer, BRAF V600 Mutation	Observational	Recruiting	2021-03	China
A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy. NCT07666555 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Culmerciclib, Fulvestrant	Phase 2	Recruiting	2026-06	China
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma NCT07762976 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 2	Recruiting	2026-08	China
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) NCT06455124 · ClinicalTrials.gov ↗ · Rectal Cancer Drugs: Capecitabine, Oxaliplatin	Phase 2	Recruiting	2024-05	China
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer NCT06447623 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, HR+/HER2- Breast Cancer Drug: Apatinib	Phase 3	Recruiting	2024-02	China
Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer NCT05059379 · ClinicalTrials.gov ↗ · Breast Cancer, Radiotherapy; Complications, Effect of Radiation Therapy	Phase 3	Recruiting	2021-09	China
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases NCT06604689 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastasases	Observational	Recruiting	2024-09	China
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer NCT06158919 · ClinicalTrials.gov ↗ · Gastric Cancer/Adenocarcinoma of Esophagogastric Junction	Not applicable	Recruiting	2023-11	China
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. NCT05760378 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer Drugs: Camrelizumab, Famitinib	Phase 3	Recruiting	2023-03	China
Incidence of 106TBL Lymph Node Metastasis NCT07165210 · ClinicalTrials.gov ↗ · Esophageal Cancer	Observational	Recruiting	2025-07	China
Sentinel Node Biopsy Vs Observation After Axillary PET NCT04072653 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Recruiting	2019-09	China
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification NCT07319429 · ClinicalTrials.gov ↗ · Endometrial Cancer, Fertility Drugs: Medroxyprogesterone Acetate, Megestrol Acetate	Phase 2/3	Recruiting	2026-01	China
Metronomic Capecitabine in Stage III Gastric Cancer NCT06313567 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	2024-03	China
The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment NCT07395960 · ClinicalTrials.gov ↗ · Mild Cognitive Impairment, Overweight or Obesity, Elderly	Phase 1/2	Recruiting	2025-09	China
Novel Therapy Target in Metastatic Prostate Cancer NCT05577689 · ClinicalTrials.gov ↗ · Prostate Neoplasms	Observational	Recruiting	2023-08	China
Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas NCT07183280 · ClinicalTrials.gov ↗ · Solid Pseudopapillary Neoplasm of the Pancreas	Observational	Recruiting	2025-09	China
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer NCT05759546 · ClinicalTrials.gov ↗ · Breast Cancer Metastatic Drugs: Dalpiciclib, Fluzoparib, Fulvestrant/AI	Phase 2	Recruiting	2023-02	China
The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota NCT07400354 · ClinicalTrials.gov ↗ · Gastric Cancer, Gut Microbiota	Observational	Recruiting	2024-03	China
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer NCT06601283 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2/3	Recruiting	2024-11	China
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC NCT07554846 · ClinicalTrials.gov ↗ · Resectable Stage II-IIIa NSCLC	Phase 3	Recruiting	2026-05	China
GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1） NCT06988592 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer	Observational	Recruiting	2025-05	China
A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor NCT06682117 · ClinicalTrials.gov ↗ · Treatment, Neoantigen, Vaccine	Not applicable	Recruiting	2024-11	China
Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC NCT07303023 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 3	Recruiting	2025-09	China
WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases NCT06243003 · ClinicalTrials.gov ↗ · SCLC,Extensive Stage, Brain Metastases	Phase 1/2	Recruiting	2024-01	China
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer NCT06970353 · ClinicalTrials.gov ↗ · Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation Drugs: Pembrolizumab/Finotonlimab, Tunlametinib	Phase 2	Recruiting	2025-05	China
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma NCT06427239 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drugs: Adebrelimab, Bevacizumab, HRS-4642	Phase 1/2	Recruiting	2024-06	China
MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC NCT07235566 · ClinicalTrials.gov ↗ · Thyroid Cancer Drugs: Becotatug Vedotin, Pucotenlimab	Phase 2	Recruiting	2025-04	China
Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy NCT06090994 · ClinicalTrials.gov ↗ · Colorectal Cancer Drugs: Capecitabine, Huaier	Phase 4	Recruiting	2024-10	China
Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery NCT07264556 · ClinicalTrials.gov ↗ · Colorectal Cancer, Opioid-free Anesthesia, NETs	Not applicable	Recruiting	2025-11	China
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT06517004 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma	Phase 1	Recruiting	2024-07	China
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) NCT05909332 · ClinicalTrials.gov ↗ · Breast Cancer, Triple Negative Breast Cancer	Phase 3	Recruiting	2023-06	China
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC NCT06676449 · ClinicalTrials.gov ↗ · Esophageal Carcinoma, Radiotherapy, Immunotherapy	Phase 3	Recruiting	2024-11	China
Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer NCT04516681 · ClinicalTrials.gov ↗ · Colorectal Cancer, Vitamin C, GLUT3 Drug: Adebrelimab	Phase 3	Recruiting	2024-12	China
ctDNA-guided Treatment Decision-making NCT07394218 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer ( HER2 Negative), ctDNA Drug: Ivonescimab	Phase 2	Recruiting	2025-12	China
The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients NCT05032768 · ClinicalTrials.gov ↗ · Radiation Dermatitis, Skin Microbiome, Breast Cancer	Observational	Recruiting	2021-01	China
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer NCT05806060 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer	Phase 3	Recruiting	2023-04	China
Precision Palliative Care for Patients With Advanced Esophageal Cancer NCT06787313 · ClinicalTrials.gov ↗ · Esophageal Cancer	Observational	Recruiting	2024-12	China
Effectiveness of Gut Microbiota-targeted Diatery Intervention Among Older People Living With HIV NCT06560840 · ClinicalTrials.gov ↗ · Hiv, Atherosclerosis, Diet, Healthy	Not applicable	Recruiting	2024-08	China
Perioperative Immunotherapy for Resectable Limited-Stage SCLC NCT07109401 · ClinicalTrials.gov ↗ · Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer Drug: Tislelizumab	Phase 2	Recruiting	2025-03	China
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC NCT04136535 · ClinicalTrials.gov ↗ · NSCLC Stage IV	Phase 2	Recruiting	2021-11	China
Real-World Study of Young Patients With Solid Tumors in China NCT07708935 · ClinicalTrials.gov ↗ · Cancer	Observational	Recruiting	2026-07	China
G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation NCT07362810 · ClinicalTrials.gov ↗ · Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation, Hemato-oncologic Patients Drug: G-Csf	Phase 2	Recruiting	2026-01	China
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations NCT07117890 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Drug: Sunvozertinib	Phase 2	Recruiting	2025-02	China
Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer NCT06684418 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer), Artificial Intelligence (AI), Lymphnode Metastasis	Observational	Recruiting	2024-12	China
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab NCT06516289 · ClinicalTrials.gov ↗ · BRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer Drugs: Camrelizumab, Famitinib, HRS-1167	Phase 2	Recruiting	2024-09	China
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy NCT07067268 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC)	Phase 2	Recruiting	2024-09	China
Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study NCT07270861 · ClinicalTrials.gov ↗ · Peripheral T-Cell Lymphoma	Observational	Recruiting	2025-11	China
Combination of TURP and Standard Systemic Therapy for MPCa NCT06655259 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer	Phase 2	Recruiting	2024-09	China
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer NCT06856200 · ClinicalTrials.gov ↗ · Advanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy Drugs: Fulvestrant, Palbociclib, Sirolimus	Not applicable	Recruiting	2025-02	China
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) NCT06860490 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC) Drugs: Bevacizumab biosimilar, Sintilimab	Phase 2	Recruiting	2025-03	China
Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer NCT07471776 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer ( HER2 Negative)	Phase 2	Recruiting	2026-03	China
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence NCT06812039 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC)	Phase 2	Recruiting	2025-01	China
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases NCT04687631 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases Drugs: Bevacizumab, Cetuximab, MFOLFOXIRI	Phase 3	Recruiting	2021-01	China
The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma NCT05839275 · ClinicalTrials.gov ↗ · High-Risk Localized Soft Tissue Sarcoma	Phase 1/2	Recruiting	2022-08	China
SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009) NCT04527419 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Not applicable	Recruiting	2022-02	China
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer NCT05901428 · ClinicalTrials.gov ↗ · Hormone Receptor Positive HER-2 Negative Breast Cancer	Phase 3	Recruiting	2023-06	China
Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study NCT07236203 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma Drug: Car-T	Observational	Recruiting	2024-02	China
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy NCT07117630 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Fulvestrant	Phase 2	Recruiting	2025-09	China
AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial NCT06642948 · ClinicalTrials.gov ↗ · Musculoskeletal Symptoms, Breast Cancer, Endocrine Therapy	Not applicable	Recruiting	2024-10	China
Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15) NCT04519905 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Survival Drugs: Carboplatin, Paclitaxel	Not applicable	Recruiting	2020-01	China
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment NCT07147101 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma (HCC)	Observational	Recruiting	2025-09	China
SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor Drugs: Apatinib, Bevacizumab, Carrelizumab	Phase 2	Recruiting	2022-12	China
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer NCT06841159 · ClinicalTrials.gov ↗ · Microsatellite Stable Metastatic Colorectal Cancer Drug: Sintilimab	Phase 2	Recruiting	2024-03	China
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer NCT06331169 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Anlotinib, Trastuzumab deruxtecan	Phase 1	Recruiting	2024-07	China
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC NCT07003022 · ClinicalTrials.gov ↗ · Colo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Drugs: Cadonilimab, Fruquintinib	Phase 2	Recruiting	2025-06	China
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy NCT07528716 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Pyrotinib, Trastuzumab Rezetecan	Phase 3	Recruiting	2026-05	China
Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue NCT07656324 · ClinicalTrials.gov ↗ · Cancer	Observational	Recruiting	2025-01	China
Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma NCT07389876 · ClinicalTrials.gov ↗ · Gastric Cancer, Second-line Treatment Drugs: Albumin-Bound Paclitaxel, Trastuzumab emtansine	Observational	Recruiting	2025-09	China

Showing the 100 most recently updated of 472 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Fudan University trials

196 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 156 more in the trial list above.

By trial register

Register	Trials	Recruiting
Clinical trials in China	472	250

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10
Xijing Hospital	9

Sponsors with the most current trials registered for this condition.

Questions about Fudan University trials

How many clinical trials does Fudan University sponsor?

Fudan University is the lead sponsor of 472 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Fudan University trials recruiting?

Yes. 308 of its 472 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Fudan University testing?

Its current trials name 196 drugs and biologicals as interventions. The most frequent are Bevacizumab (18), Tislelizumab (17), Capecitabine (16), Oxaliplatin (13) and Trastuzumab Rezetecan (12). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Fudan University clinical trials